Drug search by name

Valcyte and Hematologic toxicities

Result of checking the interaction of drug Valcyte and disease Hematologic toxicities for safety when used together.

Check result:

Valcyte <> Hematologic toxicities

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow aplasia, and aplastic anemia have been reported in patients treated with valganciclovir. The use of this agent should be avoided if the absolute neutrophil count is less than 500 cells/µL, the platelet count is less than 25,000/µ/L, or the hemoglobin is less than 8 g/dL. Complete blood counts with differential and platelet counts should be performed frequently, especially in patients that developed leukopenia after using a nucleoside analog, or in whom neutrophil counts are less than 1000 cells/µL at the beginning of treatment. Therapy with this agent should be administered with caution in patients with bone marrow depression. Increased monitoring is recommended.

Valcyte

Generic Name: valganciclovir

Brand Name: Valcyte

Synonyms: n.a.

What is Valcyte?